当前位置: 首页 >> 检索结果
1. Pulsed electromagnetic fields in knee osteoarthritis: a double blind, placebo-controlled, randomized clinical trial.
作者: Gian Luca Bagnato.;Giovanni Miceli.;Natale Marino.;Davide Sciortino.;Gian Filippo Bagnato.
来源: Rheumatology (Oxford). 2016年55卷4期755-62页
This trial aimed to test the effectiveness of a wearable pulsed electromagnetic fields (PEMF) device in the management of pain in knee OA patients.
2. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.
作者: Edward C Keystone.;Janet E Pope.;J Carter Thorne.;Melanie Poulin-Costello.;Krystene Phan-Chronis.;Andrew Vieira.;Boulos Haraoui.; .
来源: Rheumatology (Oxford). 2016年55卷2期327-34页
To evaluate radiographic and clinical outcomes up to 24 months in patients with RA enrolled in the Canadian Methotrexate and Etanercept Outcome study.
3. Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up.
作者: Perrine Guillaume-Jugnot.;Aurélie Daumas.;Jérémy Magalon.;Elisabeth Jouve.;Pierre-Sébastien Nguyen.;Romain Truillet.;Stéphanie Mallet.;Dominique Casanova.;Laurent Giraudo.;Julie Veran.;Françoise Dignat-George.;Florence Sabatier.;Guy Magalon.;Brigitte Granel.
来源: Rheumatology (Oxford). 2016年55卷2期301-6页
Impaired hand function greatly contributes to disability and reduced quality of life in SSc patients. Autologous adipose-derived stromal vascular fraction (ADSVF) is recognized as an easily accessible source of regenerative cells. We reported positive 6-month safety and efficacy results from an open-label clinical trial assessing s.c. injection of autologous ADSVF into the fingers in SSc patients. The objective of this report is to describe the effects at 12 months.
4. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial.
作者: Faith Matcham.;Sam Norton.;David L Scott.;Sophia Steer.;Matthew Hotopf.
来源: Rheumatology (Oxford). 2016年55卷2期268-78页
The aim of this analysis is to examine the longitudinal impact of symptoms of depression/anxiety on treatment response, long-term disease activity and physical disability in RA.
5. Inefficacy of ultrasound-guided local injections of autologous conditioned plasma for recent epicondylitis: results of a double-blind placebo-controlled randomized clinical trial with one-year follow-up.
作者: Bernard Montalvan.;Patrick Le Goux.;Shahnaz Klouche.;Delphine Borgel.;Philippe Hardy.;Maxime Breban.
来源: Rheumatology (Oxford). 2016年55卷2期279-85页
The aim was to assess the efficacy of two intra-tendinous injections of platelet-rich plasma (PRP) on epicondylitis of recent evolution (≤3 months).
6. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.
作者: Désirée van der Heijde.;Avani Joshi.;Aileen L Pangan.;Naijun Chen.;Keith Betts.;Manish Mittal.;Yanjun Bao.
来源: Rheumatology (Oxford). 2016年55卷1期80-8页
To assess the impact of achieving Assessment in SpondyloArthritis international Society 40% (ASAS40) response or an Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS-ID) state on patient-reported outcomes (PROs) among patients with non-radiographic axial SpA (nr-axSpA).
7. Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis.
作者: Gerd R Burmester.;Patrick Durez.;Galina Shestakova.;Mark C Genovese.;Hendrik Schulze-Koops.;Yue Li.;Ying A Wang.;Steve Lewitzky.;Irina Koroleva.;Anni Agarwal Berneis.;David M Lee.;Wolfgang Hueber.
来源: Rheumatology (Oxford). 2016年55卷1期49-55页
To assess whether preliminary findings of associations between the HLA-DRB1*04 and HLA-DRB1* shared epitope (SE) allelic groups and response to the anti-IL-17A mAb secukinumab in RA were reproducible in an independent RA cohort.
8. Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study.
作者: Massimo Varenna.;Francesca Zucchi.;Simonetta Failoni.;Andrea Becciolini.;Massimo Berruto.
来源: Rheumatology (Oxford). 2015年54卷10期1826-32页
The aim of this randomized, double-blind, placebo-controlled study was to assess the efficacy of i.v. neridronate in controlling pain in patients with acute painful knee OA.
9. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
作者: Divi Cornec.;Valérie Devauchelle-Pensec.;Xavier Mariette.;Sandrine Jousse-Joulin.;Jean-Marie Berthelot.;Aleth Perdriger.;Xavier Puéchal.;Véronique Le Guern.;Jean Sibilia.;Jacques-Eric Gottenberg.;Laurent Chiche.;Eric Hachulla.;Pierre Yves Hatron.;Vincent Goeb.;Gilles Hayem.;Jacques Morel.;Charles Zarnitsky.;Jean Jacques Dubost.;Raphaèle Seror.;Jacques-Olivier Pers.;Petra M Meiners.;Arjan Vissink.;Hendrika Bootsma.;Emmanuel Nowak.;Alain Saraux.
来源: Rheumatology (Oxford). 2015年54卷9期1699-708页
To determine which outcome measures detected rituximab efficacy in the Tolerance and Efficacy of Rituximab in Sjögren's Disease (TEARS) trial and to create a composite endpoint for future trials in primary SS (pSS).
10. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
作者: Désirée van der Heijde.;Maxime Breban.;Dale Halter.;Gino DiVittorio.;Johan Bratt.;Fabrizio Cantini.;Sonja Kary.;Aileen L Pangan.;Hartmut Kupper.;Suchitrita S Rathmann.;Joachim Sieper.;Phillip J Mease.
来源: Rheumatology (Oxford). 2015年54卷7期1210-9页
Chronic pain and progressive loss of physical function with AS may adversely affect health-related quality of life (HRQoL). The objective of this study was to assess the 5-year data regarding spinal mobility, physical function and HRQoL in patients with AS who participated in the Adalimumab Trial Evaluating Long-term Efficacy and Safety for AS (ATLAS) study.
11. A randomized controlled trial for improving patient self-assessment of synovitis in rheumatoid arthritis with education by ultrasonography: the RAEUS Study.
作者: Peter P Cheung.;Manjari Lahiri.;Gim Gee Teng.;Anita Y N Lim.;Tang Ching Lau.;Aisha Lateef.;Anselm Mak.;Laure Gossec.;Lyn March.
来源: Rheumatology (Oxford). 2015年54卷7期1161-9页
Patients can potentially monitor disease activity of RA through self-assessed swollen joints (clinical synovitis), but reliability is poor. The objective is to evaluate the use of education by US feedback on the ability of patients to assess for clinical synovitis in RA.
12. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids.
作者: Fowzia Ibrahim.;Ernest Choy.;Patrick Gordon.;Caroline J Doré.;Alan Hakim.;George Kitas.;David Isenberg.;Bridget Griffiths.;Bryan Lecky.;Kuntal Chakravarty.;John Winer.;Katalin Danko.;Robert G Cooper.;Beverley White-Alao.;David L Scott.
来源: Rheumatology (Oxford). 2015年54卷6期1050-5页
Ciclosporin and MTX are used in idiopathic inflammatory myopathies (DM and PM) when patients incompletely respond to glucocorticoids. Their effectiveness is unproved in randomized controlled trials (RCTs). We evaluated their benefits in a placebo-controlled factorial RCT.
13. Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index.
作者: Bridget Hodkinson.;Eustatius Musenge.;Mohammed Tikly.
来源: Rheumatology (Oxford). 2015年54卷6期1033-8页
The aim of this study was to explore the clinical utility of the clinical disease activity index (CDAI). We compared the disease control with protocolized treatment adjustment following a tight control strategy utilizing either the simplified disease activity index (SDAI) or the CDAI.
14. Joint protection and hand exercises for hand osteoarthritis: an economic evaluation comparing methods for the analysis of factorial trials.
作者: Raymond Oppong.;Sue Jowett.;Elaine Nicholls.;David G T Whitehurst.;Susan Hill.;Alison Hammond.;Elaine M Hay.;Krysia Dziedzic.
来源: Rheumatology (Oxford). 2015年54卷5期876-83页
Evidence regarding the cost-effectiveness of joint protection and hand exercises for the management of hand OA is not well established. The primary aim of this study is to assess the cost-effectiveness (cost-utility) of these management options. In addition, given the absence of consensus regarding the conduct of economic evaluation alongside factorial trials, we compare different analytical methodologies.
15. Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.
作者: Victoria L Manning.;Billingsley Kaambwa.;Julie Ratcliffe.;David L Scott.;Ernest Choy.;Michael V Hurley.;Lindsay M Bearne.
来源: Rheumatology (Oxford). 2015年54卷2期302-9页
The aim of this study was to conduct a cost-utility analysis of the Education, Self-management and Upper Limb Exercise Training in People with RA (EXTRA) programme compared with usual care.
16. Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial.
作者: In-Ho Song.;Kay-Geert Hermann.;Hildrun Haibel.;Christian E Althoff.;Denis Poddubnyy.;Joachim Listing.;Anja Weiß.;Ekkehard Lange.;Bruce Freundlich.;Martin Rudwaleit.;Joachim Sieper.
来源: Rheumatology (Oxford). 2015年54卷2期257-61页
The aim of this study was to assess the degree of fluctuation of osteitis on MRI during long-term treatment with etanercept (ETN) in patients with early axial SpA (axSpA) with active inflammation (osteitis) on whole-body MRI in the spine and/or the SI joints at baseline.
17. Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study.
作者: Giuseppe Germanò.;Francesco Muratore.;Luca Cimino.;Alberto Lo Gullo.;Niccolò Possemato.;Pierluigi Macchioni.;Alberto Cavazza.;Nicolò Pipitone.;Luigi Boiardi.;Carlo Salvarani.
来源: Rheumatology (Oxford). 2015年54卷3期400-4页
The aim of this study was to assess the usefulness of colour duplex sonography (CDS)-guided temporal artery biopsy (TAB) for the diagnosis of GCA in patients with suspected GCA.
18. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.
作者: Bente Glintborg.;Bjorn Gudbjornsson.;Niels Steen Krogh.;Emina Omerovic.;Natalia Manilo.;Mette Holland-Fischer.;Hanne M Lindegaard.;Anne Gitte Loft.;Henrik Nordin.;Laura Johnsen.;Sussi Flejsborg Oeftiger.;Annette Hansen.;Claus Rasmussen.;Gerdur Grondal.;Arni Jon Geirsson.;Merete Lund Hetland.
来源: Rheumatology (Oxford). 2014年53卷11期2100-9页
The aim of this study was to describe dose regimens, dose escalation and clinical outcomes in TNF-α inhibitor (TNFi)-naive patients with PsA treated with infliximab in routine rheumatology care.
19. Does ultrasound-scored synovitis depend on the pharmacokinetics of subcutaneous anti-TNF agents in patients with rheumatoid arthritis?
作者: Esperanza Naredo.;Michelle Hinojosa.;Lara Valor.;Diana Hernández-Flórez.;Carmen Mata-Martínez.;Belén Serrano-Benavente.;Tamara Del Río.;Natalia Bello.;María Montoro.;Juan Carlos Nieto-González.;Carlos M González.;Francisco Javier López-Longo.;Indalecio Monteagudo.;Luis Carreño.
来源: Rheumatology (Oxford). 2014年53卷11期2088-94页
The aim of this study was to investigate the influence of the pharmacokinetics of s.c. anti-TNF agents on the grade of US-detected synovitis in RA patients.
20. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
作者: Roy Fleischmann.;Andrew S Koenig.;Annette Szumski.;Henk W Nab.;Lisa Marshall.;Eustratios Bananis.
来源: Rheumatology (Oxford). 2014年53卷11期1984-93页
The aims of this study were to investigate the short-term benefit of etanercept (ETN) + MTX vs conventional synthetic DMARDs (csDMARDs; HCQ, LEF or SSZ) + MTX in subjects with established RA. The effect of disease duration (≤2 years vs >2 years) and severity (moderate vs severe) on treatment outcomes was also assessed. Methods. Data from Asian and Latin American subjects with inadequate response to MTX were pooled from the APPEAL (ETN 25 mg biweekly + MTX or csDMARD + MTX; NCT00422227) and Latin RA (ETN 50 mg/week + MTX or csDMARD + MTX; NCT00848354) studies. Endpoints included the 28-joint DAS with ESR (DAS28-ESR) low disease activity (LDA; ≤3.2), DAS28 remission (<2.6) and HAQ score ≤0.5.
|